



MEN

FIRST CANCER SITE

KIDNEY AND RENAL PELVIS

KIDNEY AND RENAL PELVIS
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

RENE E PELVI RENALE
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

| months after first cancer ▶ | ≥2 months | | ≥0 months | | 0-1 months | | 2-11 months | | 12-59 months | | 60-119 months | | ≥120 months | | ≥2 months | ≥0 months |
|---|-----------|------|-----------|------|------------|-------|-------------|------|--------------|------|---------------|------|-------------|------|-----------|-----------|
| No. of subjects alive at interval beginning ▶ | 25527 | | 28344 | | 28344 | | 25527 | | 19549 | | 9127 | | 3422 | | 25527 | 28344 |
| Person-years ▶ | 114765 | | 119223 | | 4457 | | 18399 | | 53593 | | 29666 | | 13108 | | 114765 | 119223 |
| SECOND CANCER SITE | O | SIR | O | SIR | O | SIR | O | SIR | O | SIR | O | SIR | O | SIR | EAR | EAR |
| ALL SITES, BUT SKIN AND KIDNEY AND RENAL PELVIS | 2476 | 1.14 | 3079 | 1.37 | 603 | 7.68 | 424 | 1.33 | 1097 | 1.13 | 656 | 1.11 | 299 | 1.01 | 2.62 | 6.92 |
| HEAD AND NECK | 91 | 0.97 | 96 | 0.99 | 5 | 1.37 | 14 | 0.94 | 43 | 0.99 | 22 | 0.91 | 12 | 1.12 | -0.02 | -0.01 |
| ORAL CAVITY | 24 | 1.09 | 25 | 1.09 | 1 | 1.18 | 6 | 1.73 | 9 | 0.88 | 6 | 1.04 | 3 | 1.16 | 0.02 | 0.02 |
| PHARYNX | 21 | 1.05 | 21 | 1.01 | 0 | 0.00 | 1 | 0.31 | 10 | 1.06 | 7 | 1.35 | 3 | 1.33 | 0.01 | 0.00 |
| LARYNX | 46 | 0.90 | 50 | 0.94 | 4 | 1.98 | 7 | 0.85 | 24 | 1.00 | 9 | 0.68 | 6 | 1.02 | -0.05 | -0.03 |
| OESOPHAGUS | 9 | 0.38 | 17 | 0.69 | 8 | 8.90 | 1 | 0.27 | 5 | 0.46 | 3 | 0.48 | 0 | 0.00 | -0.13 | -0.06 |
| STOMACH | 121 | 0.91 | 129 | 0.94 | 8 | 1.58 | 24 | 1.20 | 49 | 0.83 | 34 | 0.96 | 14 | 0.81 | -0.10 | -0.07 |
| COLON RECTUM | 325 | 1.06 | 336 | 1.06 | 11 | 1.01 | 40 | 0.90 | 145 | 1.07 | 101 | 1.20 | 39 | 0.90 | 0.16 | 0.15 |
| COLON | 243 | 1.15 | 254 | 1.16 | 11 | 1.49 | 29 | 0.96 | 107 | 1.16 | 76 | 1.31 | 31 | 1.03 | 0.28 | 0.30 |
| RECTUM | 82 | 0.85 | 82 | 0.82 | 0 | 0.00 | 11 | 0.77 | 38 | 0.88 | 25 | 0.95 | 8 | 0.62 | -0.13 | -0.15 |
| LIVER | 68 | 0.76 | 91 | 0.98 | 23 | 7.08 | 9 | 0.68 | 23 | 0.57 | 19 | 0.79 | 17 | 1.43 | -0.19 | -0.01 |
| GALLBLADDER | 18 | 0.78 | 18 | 0.75 | 0 | 0.00 | 4 | 1.19 | 9 | 0.89 | 4 | 0.63 | 1 | 0.30 | -0.04 | -0.05 |
| PANCREAS | 71 | 1.18 | 75 | 1.20 | 4 | 1.86 | 11 | 1.26 | 25 | 0.94 | 22 | 1.34 | 13 | 1.54 | 0.09 | 0.11 |
| LUNG | 357 | 0.91 | 476 | 1.17 | 119 | 8.14 | 39 | 0.66 | 159 | 0.90 | 108 | 1.03 | 51 | 1.00 | -0.30 | 0.59 |
| SKIN MELANOMA | 50 | 1.54 | 55 | 1.63 | 5 | 4.45 | 13 | 2.78 | 21 | 1.46 | 14 | 1.57 | 2 | 0.44 | 0.15 | 0.18 |
| MESOTHELIOMA | 15 | 1.25 | 18 | 1.46 | 3 | 7.25 | 3 | 1.76 | 5 | 0.95 | 6 | 1.83 | 1 | 0.59 | 0.03 | 0.05 |
| KAPOSI SARCOMA | 2 | 0.45 | 3 | 0.64 | 1 | 5.92 | 0 | 0.00 | 1 | 0.50 | 0 | 0.00 | 1 | 1.66 | -0.02 | -0.01 |
| SOFT TISSUE | 9 | 1.16 | 14 | 1.75 | 5 | 17.86 | 1 | 0.87 | 5 | 1.45 | 3 | 1.43 | 0 | 0.00 | 0.01 | 0.05 |
| BONE | 2 | 1.00 | 2 | 0.97 | 0 | 0.00 | 0 | 0.00 | 1 | 1.10 | 1 | 1.91 | 0 | 0.00 | 0.00 | 0.00 |
| BREAST | 8 | 1.68 | 8 | 1.62 | 0 | 0.00 | 0 | 0.00 | 5 | 2.35 | 2 | 1.54 | 1 | 1.54 | 0.03 | 0.03 |
| PROSTATE | 670 | 1.50 | 872 | 1.89 | 202 | 13.44 | 138 | 2.24 | 284 | 1.46 | 169 | 1.35 | 79 | 1.22 | 1.95 | 3.45 |
| TESTIS | 5 | 1.83 | 6 | 2.11 | 1 | 8.88 | 1 | 2.13 | 3 | 2.27 | 0 | 0.00 | 1 | 3.65 | 0.02 | 0.03 |
| KIDNEY AND RENAL PELVIS | 3 | 0.04 | 35 | 0.47 | 32 | 12.50 | 1 | 0.10 | 1 | 0.03 | 1 | 0.05 | 0 | 0.00 | -0.60 | -0.33 |
| BLADDER AND URINARY TRACT | 323 | 1.31 | 479 | 1.87 | 156 | 17.38 | 82 | 2.25 | 154 | 1.40 | 61 | 0.91 | 26 | 0.77 | 0.66 | 1.87 |
| URINARY BLADDER | 313 | 1.33 | 459 | 1.88 | 146 | 16.99 | 81 | 2.33 | 149 | 1.42 | 59 | 0.92 | 24 | 0.75 | 0.67 | 1.80 |
| URINARY TRACT | 10 | 0.94 | 20 | 1.82 | 10 | 26.07 | 1 | 0.65 | 5 | 1.07 | 2 | 0.69 | 2 | 1.33 | -0.01 | 0.08 |
| BRAIN AND CENTRAL NERVOUS SYSTEM | 25 | 0.97 | 25 | 0.93 | 0 | 0.00 | 5 | 1.27 | 10 | 0.85 | 5 | 0.73 | 5 | 1.54 | -0.01 | -0.01 |
| THYROID | 25 | 2.36 | 28 | 2.56 | 3 | 7.94 | 2 | 1.26 | 13 | 2.71 | 5 | 1.75 | 5 | 3.74 | 0.13 | 0.14 |
| HODGKIN LYMPHOMA | 4 | 0.89 | 8 | 1.71 | 4 | 22.58 | 2 | 2.76 | 1 | 0.48 | 1 | 0.86 | 0 | 0.00 | 0.00 | 0.03 |
| NON-HODGKIN LYMPHOMA | 81 | 1.27 | 89 | 1.35 | 8 | 3.49 | 9 | 0.96 | 40 | 1.41 | 21 | 1.22 | 11 | 1.29 | 0.15 | 0.19 |
| MYELOMA | 38 | 1.31 | 42 | 1.40 | 4 | 3.81 | 5 | 1.18 | 17 | 1.33 | 9 | 1.14 | 7 | 1.74 | 0.08 | 0.10 |
| LEUKAEMIAS | 58 | 1.17 | 76 | 1.48 | 18 | 9.80 | 7 | 0.95 | 30 | 1.36 | 16 | 1.19 | 5 | 0.75 | 0.07 | 0.21 |
| LYMPHOID LEUKAEMIAS | 20 | 0.84 | 37 | 1.49 | 17 | 19.05 | 4 | 1.11 | 7 | 0.65 | 7 | 1.09 | 2 | 0.64 | -0.03 | 0.10 |
| MYELOID LEUKAEMIAS | 36 | 1.60 | 37 | 1.59 | 1 | 1.23 | 3 | 0.92 | 22 | 2.22 | 8 | 1.30 | 3 | 0.95 | 0.12 | 0.12 |
| OTHER LEUKAEMIAS | 2 | 0.61 | 2 | 0.58 | 0 | 0.00 | 0 | 0.00 | 1 | 0.68 | 1 | 1.14 | 0 | 0.00 | -0.01 | -0.01 |
| OTHER AND ILL DEFINED SITES | 101 | 0.89 | 116 | 0.99 | 15 | 3.66 | 14 | 0.85 | 49 | 0.99 | 30 | 0.97 | 8 | 0.50 | -0.10 | -0.01 |

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE

KIDNEY AND RENAL PELVIS**KIDNEY AND RENAL PELVIS
POOL AIRTUM 1976-2010, WOMEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**RENE E PELVI RENALE
POOL AIRTUM 1976-2010, DONNE:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

| months after first cancer ▶ | ≥2 months | | ≥0 months | | 0-1 months | | 2-11 months | | 12-59 months | | 60-119 months | | ≥120 months | | ≥2 months | ≥0 months |
|--|---|----------------|-----------|-------------|------------|--------------|-------------|-------------|--------------|-------------|---------------|-------------|-------------|-------------|--------------|--------------|
| | No. of subjects alive at interval beginning ▶ | Person-years ▶ | O | SIR | O | SIR | O | SIR | O | SIR | O | SIR | O | SIR | EAR | EAR |
| SECOND CANCER SITE | 0 | SIR | 0 | SIR | 0 | SIR | 0 | SIR | 0 | SIR | 0 | SIR | 0 | SIR | EAR | EAR |
| ALL SITES, BUT SKIN AND KIDNEY AND RENAL PELVIS | 858 | 1.15 | 1058 | 1.37 | 200 | 7.49 | 161 | 1.49 | 361 | 1.10 | 219 | 1.07 | 117 | 1.13 | 1.68 | 4.09 |
| HEAD AND NECK | 3 | 0.31 | 4 | 0.40 | 1 | 2.89 | 1 | 0.71 | 1 | 0.23 | 1 | 0.38 | 0 | 0.00 | -0.10 | -0.09 |
| ORAL CAVITY | 2 | 0.38 | 2 | 0.37 | 0 | 0.00 | 1 | 1.35 | 0 | 0.00 | 1 | 0.69 | 0 | 0.00 | -0.05 | -0.05 |
| PHARYNX | 1 | 0.48 | 1 | 0.46 | 0 | 0.00 | 0 | 0.00 | 1 | 1.06 | 0 | 0.00 | 0 | 0.00 | -0.02 | -0.02 |
| LARYNX | 0 | 0.00 | 1 | 0.41 | 1 | 11.62 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | -0.03 | -0.02 |
| OESOPHAGUS | 1 | 0.27 | 1 | 0.26 | 0 | 0.00 | 1 | 1.88 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | -0.04 | -0.04 |
| STOMACH | 30 | 0.68 | 34 | 0.74 | 4 | 2.38 | 3 | 0.46 | 13 | 0.67 | 10 | 0.83 | 4 | 0.65 | -0.21 | -0.17 |
| COLON RECTUM | 136 | 1.15 | 139 | 1.13 | 3 | 0.71 | 23 | 1.36 | 55 | 1.07 | 35 | 1.06 | 23 | 1.35 | 0.26 | 0.23 |
| COLON | 98 | 1.15 | 100 | 1.13 | 2 | 0.66 | 18 | 1.48 | 37 | 1.00 | 27 | 1.14 | 16 | 1.29 | 0.19 | 0.17 |
| RECTUM | 38 | 1.15 | 39 | 1.13 | 1 | 0.83 | 5 | 1.04 | 18 | 1.24 | 8 | 0.87 | 7 | 1.51 | 0.07 | 0.07 |
| LIVER | 20 | 0.97 | 33 | 1.55 | 13 | 17.65 | 4 | 1.36 | 7 | 0.78 | 5 | 0.87 | 4 | 1.33 | -0.01 | 0.17 |
| GALLBLADDER | 5 | 0.31 | 7 | 0.42 | 2 | 3.36 | 0 | 0.00 | 3 | 0.43 | 2 | 0.45 | 0 | 0.00 | -0.16 | -0.14 |
| PANCREAS | 46 | 1.49 | 47 | 1.47 | 1 | 0.92 | 7 | 1.62 | 9 | 0.68 | 14 | 1.61 | 16 | 3.40 | 0.22 | 0.21 |
| LUNG | 64 | 1.30 | 87 | 1.71 | 23 | 13.51 | 15 | 2.17 | 29 | 1.36 | 14 | 1.02 | 6 | 0.83 | 0.22 | 0.51 |
| SKIN MELANOMA | 17 | 1.23 | 20 | 1.40 | 3 | 6.23 | 2 | 1.01 | 10 | 1.63 | 4 | 1.05 | 1 | 0.52 | 0.05 | 0.08 |
| MESOTHELIOMA | 1 | 0.48 | 1 | 0.46 | 0 | 0.00 | 0 | 0.00 | 1 | 1.10 | 0 | 0.00 | 0 | 0.00 | -0.02 | -0.02 |
| KAPOSI SARCOMA | 1 | 1.00 | 1 | 0.97 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 3.64 | 0 | 0.00 | 0.00 | 0.00 |
| SOFT TISSUE | 10 | 3.17 | 13 | 3.97 | 3 | 26.72 | 1 | 2.19 | 5 | 3.60 | 3 | 3.45 | 1 | 2.25 | 0.10 | 0.14 |
| BONE | 1 | 1.17 | 1 | 1.13 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 4.28 | 0 | 0.00 | 0.00 | 0.00 |
| BREAST | 211 | 1.11 | 280 | 1.42 | 69 | 10.08 | 42 | 1.49 | 88 | 1.03 | 57 | 1.10 | 24 | 0.95 | 0.30 | 1.17 |
| CERVIX UTERI | 9 | 0.94 | 10 | 1.01 | 1 | 2.67 | 4 | 2.62 | 3 | 0.68 | 2 | 0.80 | 0 | 0.00 | -0.01 | 0.00 |
| CORPUS UTERI | 40 | 1.15 | 52 | 1.44 | 12 | 9.52 | 3 | 0.58 | 25 | 1.59 | 5 | 0.53 | 7 | 1.55 | 0.08 | 0.23 |
| OVARY | 20 | 0.85 | 21 | 0.86 | 1 | 1.16 | 1 | 0.28 | 10 | 0.95 | 6 | 0.94 | 3 | 0.96 | -0.05 | -0.05 |
| KIDNEY AND RENAL PELVIS | 1 | 0.05 | 4 | 0.21 | 3 | 4.57 | 1 | 0.37 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | -0.26 | -0.22 |
| BLADDER AND URINARY TRACT | 76 | 2.61 | 109 | 3.61 | 33 | 31.88 | 22 | 5.31 | 38 | 3.01 | 12 | 1.48 | 4 | 0.94 | 0.69 | 1.12 |
| URINARY BLADDER | 75 | 2.77 | 107 | 3.82 | 32 | 33.24 | 21 | 5.45 | 38 | 3.23 | 12 | 1.59 | 4 | 1.02 | 0.71 | 1.12 |
| URINARY TRACT | 1 | 0.49 | 2 | 0.94 | 1 | 13.75 | 1 | 3.47 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | -0.02 | 0.00 |
| BRAIN AND CENTRAL NERVOUS SYSTEM | 11 | 0.98 | 11 | 0.95 | 0 | 0.00 | 1 | 0.62 | 3 | 0.61 | 5 | 1.63 | 2 | 1.29 | 0.00 | -0.01 |
| THYROID | 37 | 2.81 | 40 | 2.93 | 3 | 6.62 | 4 | 2.09 | 14 | 2.36 | 13 | 3.61 | 6 | 3.44 | 0.35 | 0.38 |
| HODGKIN LYMPHOMA | 1 | 0.56 | 2 | 1.08 | 1 | 14.81 | 0 | 0.00 | 1 | 1.24 | 0 | 0.00 | 0 | 0.00 | -0.01 | 0.00 |
| NON-HODGKIN LYMPHOMA | 37 | 1.29 | 42 | 1.41 | 5 | 4.92 | 6 | 1.45 | 12 | 0.95 | 16 | 2.02 | 3 | 0.75 | 0.12 | 0.18 |
| MYELOMA | 12 | 0.90 | 14 | 1.01 | 2 | 4.17 | 5 | 2.59 | 6 | 1.03 | 0 | 0.00 | 1 | 0.53 | -0.02 | 0.00 |
| LEUKAEMIAS | 22 | 1.18 | 26 | 1.34 | 4 | 5.87 | 2 | 0.74 | 10 | 1.22 | 6 | 1.16 | 4 | 1.52 | 0.05 | 0.09 |
| LYMPHOID LEUKAEMIAS | 10 | 1.22 | 13 | 1.52 | 3 | 9.81 | 1 | 0.82 | 5 | 1.37 | 3 | 1.33 | 1 | 0.90 | 0.03 | 0.06 |
| MYELOID LEUKAEMIAS | 9 | 1.01 | 10 | 1.09 | 1 | 3.15 | 1 | 0.79 | 4 | 1.03 | 2 | 0.81 | 2 | 1.55 | 0.00 | 0.01 |
| OTHER LEUKAEMIAS | 3 | 1.92 | 3 | 1.85 | 0 | 0.00 | 0 | 0.00 | 1 | 1.49 | 1 | 2.30 | 1 | 4.36 | 0.02 | 0.02 |
| OTHER AND ILL DEFINED SITES | 47 | 0.85 | 63 | 1.10 | 16 | 8.04 | 14 | 1.79 | 18 | 0.76 | 7 | 0.46 | 8 | 0.97 | -0.12 | 0.08 |

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio